Navigation Links
Atrium Responds to Bard Suit
Date:8/17/2010

HUDSON, N.H., Aug. 18 /PRNewswire/ -- Atrium Medical Corporation was recently named as a defendant, along with Endologix, Inc., of Irvine, CA, in a lawsuit brought by C.R. Bard in U.S. District Court in Arizona.  The suit involves a patent, U.S. No. 6,436,135, issued to Bard in 2002 related to prosthetic vascular grafts made of ePTFE (expanded polytetrafluoroethylene). Atrium has been involved in discussions with Bard management regarding this patent for several years.

The patent was filed in 1974 and has been the subject almost continuous litigation for nearly thirty years between Bard and W. L. Gore Associates before the U.S. Patent Office and the courts. That litigation is still ongoing, and involves questions about the validity and scope of the patent that will ultimately have to be resolved by the court of appeals. Final resolution, however, will take upwards of two years or more.

Steve Herweck, Chairman and Chief Executive Officer of Atrium, said, "Atrium's management has every intention to resolve this issue in the best interest of our firm, employees and shareholders. Atrium remains committed to our almost 30 year history and practice of not knowingly violating anyone's intellectual property. Litigation by many companies today has unfortunately become an integral and daily part of business practice by many, including those in the diverse healthcare industry. We remain confident in attaining a resolution to this suit filed by Bard, and remain steadfast in our commitment to uninterrupted supply of all of our products, and our legacy of the 'best-in-the-industry' customer service to our customers."

Endologix also responded to the suit in a statement last week, saying it was confident its products do not infringe Bard's patent.

About Atrium

Founded in 1981, Atrium is a diversified healthcare provider dedicated to innovation, research and development, state-of-the-art manufacturing, customer service, and clinical education. From the cardiac cath-lab to the operating room, Atrium offers a diversified portfolio of critical care products leading the way to brighter, more clinically effective solutions in cardiovascular disease, soft tissue repair and critical care management.


'/>"/>
SOURCE Atrium Medical Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Atrium Medical Corporation Announces First Implant of First-in-Man CINATRA(TM) Voclosporin Coated Coronary Stent
2. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
3. Roche responds to announcement of IDEAL hepatitis C trial results
4. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
5. GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citizen Petition
6. AstraZeneca Responds to FDA Joint Advisory Committees Recommendation on SYMBICORT(R)
7. EPSScentral Responds to Pandemic Alert
8. Endologix Responds to Alleged Patent Infringement
9. U.S. Kidney Dialysis Community Responds to Haitis Emergency Plea for Life-Saving Dialysis Care
10. Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers
11. Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... DUBLIN , Mar. 24, 2017 Research and ... (IPF) Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with ... Corporation, Merck & Co., Inc., Biogen and Sanofi are involved in the ... candidates, of which one is in Phase III stage, 15 are in ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... their offering. ... provides separate comprehensive analytics for the US, Canada , ... Asia-Pacific , Latin America , and Rest of ... 2022. Also, a six-year historic analysis is provided for these markets. Market ...
(Date:3/24/2017)... , March 23, 2017  Provectus Biopharmaceuticals, Inc. ... "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, ... Financing Commitment Term Sheet (the "Definitive Financing") it ... of the Company,s stockholders, who are referred to ... a Form 8-K filed with the Securities and ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health ... partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is to ... Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. Food ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... Certified Medical Reiki™ Master in Frederick, MD. Judy says, “I am passionate about ... what is often a very difficult and challenging time.” , A Certified Medical ...
(Date:3/24/2017)... ... , ... “End Time GPS”: a dauntless and enlightened study of the ... is the creation of published author, Wesley Gerboth, a World War II veteran, with ... projects. Now, at age ninety-one, he shares the Wisdom God bestowed upon him in ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... collection of inspiring stories about real people of God in congregations across the ... John Miller, a Presbyterian minister ordained in 1964 who has served congregations in ...
(Date:3/23/2017)... & Seattle, WA (PRWEB) , ... March 23, 2017 , ... ... health emergency and now estimates that there could be four million Zika-related cases in ... epidemics to date with numbers of US cases reported per year skyrocketing to an ...
Breaking Medicine News(10 mins):